Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT ID: NCT05518578
Last Updated: 2023-03-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
35 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-02-07
Study Completion Date
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
NCT06798896
Focal Onset Seizures
RECRUITING
PHASE2
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
NCT07141329
Focal Onset Seizures
RECRUITING
PHASE2
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
NCT05533814
Epilepsy
COMPLETED
PHASE4
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
NCT03474770
Focal Impaired Awareness Seizures
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
NCT03288129
Partial Onset Seizures
Secondarily Generalized Seizures
Primary Generalized Tonic-Clonic Seizures
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, three-phase, long-term open-label study assessing the safety and tolerability of SPN-817 in adults 18-70 years of age with treatment resistant epilepsy. The Screening period is up to 8 weeks in duration. For eligible participants, Treatment period is 20 weeks in duration followed by an optional Open-Label Extension period which is up to 52 weeks in duration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Epilepsy
Seizures, Epileptic
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open-Label Treatment
0.25 mg to 4 mg SPN-817 taken orally twice daily
Group Type
EXPERIMENTAL
SPN-817
Intervention Type
DRUG
oral capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPN-817
oral capsule
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
(-)-Huperzine A extended-release
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. A diagnosis of treatment resistant epilepsy as adjudicated by the Epilepsy Study Consortium.
2. Is male or female, aged 18 to ≤ 70 years at screening.
3. Is able to read, understand, and sign the Informed Consent Form (ICF). If the participant is unable to sign informed consent, a Legally Authorized Representative (LAR) will complete the ICF.
4. Ability to keep accurate seizure diaries (with the aid of a caregiver as needed).
5. Weight within the normal or overweight ranges according to accepted values of the Body Mass Index Chart (18.0 to 35 kg/m2).
6. Is able to swallow capsules whole without crushing, chewing, or cutting.
7. Is willing to adhere to all study procedures and able to attend study visits within the specified time windows.
8. Failure of at least 2 tolerated, appropriately chosen and adequately dosed ASM drug schedules to achieve sustained seizure freedom.
9. Taking at least 1 ASM at Screening and Baseline.
10. At least 4 seizures accepted by the Epilepsy Study Consortium for the secondary outcome (adjudicated as "probable seizures" that are countable) during the 42-day baseline seizure diary period, and no more than a 21-day period that was seizure-free.
11. A clinical diagnosis of Focal Cortical Dysplasia (FCD) Type I or Type II (approximately n=10) confirmed by:
1. Likely FCD supported by neuroimaging that has been performed in the last 5 years, or
2. History of surgical resection of the cortical dysplasia that is histopathologically confirmed in patients who continue to have uncontrolled seizures without a compelling alternate explanation for ongoing seizures.
Note: The Epilepsy Study Consortium will review to confirm FCD/probable FCD diagnosis.
12. Be in good general health in the judgment of the PI based upon medical history, physical examination, standard 12-lead ECG, and clinical laboratory evaluations obtained during the Screening Period
13. Be able to comply with all study-specified procedures.
14. Non-pregnant females of childbearing potential (FOCP) who are either sexually inactive (abstinent) or, if sexually active with a male partner who is biologically capable of having children, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose of SPN-817, throughout the study, and for 30 days following the last dose:
1. Simultaneous use of male condom and intra-uterine contraceptive device (IUD) placed at least 4 weeks prior to first SPN-817 administration
2. Surgically sterile male partner
3. Simultaneous use of male condom and diaphragm with spermicide
4. Established hormonal contraceptive
Females are considered not to be of childbearing potential if they are either post-menopausal (amenorrhea for at least 2 years and serum follicle stimulating hormone \[FSH\] level of \>40 IU/L) or permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral oophorectomy) for 6 months minimum.
15. Males must:
1. Use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from the Screening Visit to ≥ 1 month after the last dose of SPN-817, or
2. Have been surgically sterilized prior to the Screening Visit.
3. Refrain from donating any sperm until completion of the EOS Visit.
16. Patients who were previously enrolled in the BNI-02-1b FIAS study and benefited from the treatment, following the approval by both the PI and the sponsor to be enrolled in this study.
2. Is male or female, aged 18 to ≤ 70 years at screening.
3. Is able to read, understand, and sign the Informed Consent Form (ICF). If the participant is unable to sign informed consent, a Legally Authorized Representative (LAR) will complete the ICF.
4. Ability to keep accurate seizure diaries (with the aid of a caregiver as needed).
5. Weight within the normal or overweight ranges according to accepted values of the Body Mass Index Chart (18.0 to 35 kg/m2).
6. Is able to swallow capsules whole without crushing, chewing, or cutting.
7. Is willing to adhere to all study procedures and able to attend study visits within the specified time windows.
8. Failure of at least 2 tolerated, appropriately chosen and adequately dosed ASM drug schedules to achieve sustained seizure freedom.
9. Taking at least 1 ASM at Screening and Baseline.
10. At least 4 seizures accepted by the Epilepsy Study Consortium for the secondary outcome (adjudicated as "probable seizures" that are countable) during the 42-day baseline seizure diary period, and no more than a 21-day period that was seizure-free.
11. A clinical diagnosis of Focal Cortical Dysplasia (FCD) Type I or Type II (approximately n=10) confirmed by:
1. Likely FCD supported by neuroimaging that has been performed in the last 5 years, or
2. History of surgical resection of the cortical dysplasia that is histopathologically confirmed in patients who continue to have uncontrolled seizures without a compelling alternate explanation for ongoing seizures.
Note: The Epilepsy Study Consortium will review to confirm FCD/probable FCD diagnosis.
12. Be in good general health in the judgment of the PI based upon medical history, physical examination, standard 12-lead ECG, and clinical laboratory evaluations obtained during the Screening Period
13. Be able to comply with all study-specified procedures.
14. Non-pregnant females of childbearing potential (FOCP) who are either sexually inactive (abstinent) or, if sexually active with a male partner who is biologically capable of having children, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose of SPN-817, throughout the study, and for 30 days following the last dose:
1. Simultaneous use of male condom and intra-uterine contraceptive device (IUD) placed at least 4 weeks prior to first SPN-817 administration
2. Surgically sterile male partner
3. Simultaneous use of male condom and diaphragm with spermicide
4. Established hormonal contraceptive
Females are considered not to be of childbearing potential if they are either post-menopausal (amenorrhea for at least 2 years and serum follicle stimulating hormone \[FSH\] level of \>40 IU/L) or permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral oophorectomy) for 6 months minimum.
15. Males must:
1. Use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from the Screening Visit to ≥ 1 month after the last dose of SPN-817, or
2. Have been surgically sterilized prior to the Screening Visit.
3. Refrain from donating any sperm until completion of the EOS Visit.
16. Patients who were previously enrolled in the BNI-02-1b FIAS study and benefited from the treatment, following the approval by both the PI and the sponsor to be enrolled in this study.
Exclusion Criteria
1. Has taken huperzine A within the past year, with the exception of patients who were previously enrolled in the BNI-02-1b FIAS study, benefited from the treatment, and approved by the PI and the sponsor to be enrolled in this study.
2. Is planning to become pregnant or impregnate spouse, not using an acceptable method of birth control (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant, or nursing.
3. Patients with combined focal and generalized syndrome as evidenced by severe developmental delay and multiple seizure types, confirmed by EEG (e.g., Lennox-Gastaut syndrome). Patient should also be excluded in case of non-diagnostic information.
4. Has non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
5. Has only seizures that are difficult to count; for example, has seizures that are not clinically observable.
6. Has a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
7. Has a history of status epilepticus in the 6 months prior to Screening.
8. Change in ASM regimen in the last 28 days prior to Screening. No changes in ASMs are allowed throughout the study period.
9. Vagus nerve stimulation (VNS), deep brain stimulation (DBS), responsive neurostimulator system (RNS), or other neurostimulation for epilepsy device implanted or activated \<1 year prior to Screening; stimulation parameters that have been stable for \<3 months; battery life of unit not anticipated to extend for duration of trial; or epilepsy surgery \<1 year prior to Screening.
10. Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt. History of suicidal ideation.
11. Any condition that may impact a patient's ability to follow study procedures or a patient's safety, based on what is known about the pharmacology/toxicology profile of the trial agent(s).
12. Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the PI's opinion, could interfere with the patient's suitability for participation in the study.
13. Has a history or evidence of current significant psychiatric disturbance (e.g., schizophrenia, schizoaffective, or bipolar disorder) that would preclude meaningful participation in the study procedures.
14. A history in the past 2 years or evidence of current alcohol and/or substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders 5th edition.
15. Has had any clinical laboratory abnormalities within the 2 months prior to screening considered of clinical significance by the PI.
16. Is HIV/Hepatitis B/Hepatitis C positive or has a positive urine drug screen.
17. Tobacco use as indicated by \>5 cigarettes per week or the equivalent, 30 days prior to Day -1.
18. Is on concomitant therapy with non-ASMs that are cholinergic.
19. Is currently taking or within the 3 days prior to enrollment has taken Epigallocatechin gallate (EGCG); or consumed foods or drinks containing EGCG, including green, white, or oolong teas and certain black teas, or food containing \>100 grams of carob powder. EGCG cannot be consumed throughout the study.
20. Has participated in any clinical investigational drug or device study within 4 weeks prior to study entry or within 5 half-lives of the clinical investigational drug, whichever is longer.
21. Clinically significant cardiologic abnormalities at Screening. One repeat assessment is allowed per investigator discretion.
1. Abnormal ECG that is, in the investigator's opinion, clinically significant including heart rate (HR) \<50 bpm (average of 3 recordings)
2. PR interval \> 220 ms
3. QRS interval ≥ 120 ms
4. QTcF (QT corrected for heart rate using Fridericia's method) interval \> 450 ms for males and interval \> 475 ms for females
5. Second or third-degree atrioventricular block
6. Any rhythm, other than sinus rhythm, that is interpreted by the investigator to be clinically significant
22. Creatinine clearance \< 90 mL/min, according to the Cockcroft-Gault equation at Screening.
23. Clinically significant vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or HR less than 50 or over 100 bpm) at Screening.
24. Patient has had greater than 2 allergic reactions to an ASM or one serious hypersensitivity reaction to an ASM.
25. Patients who donated 50 to 499 mL of blood within 30 days or more than 499 mL within 56 days prior to Day 1 dosing or have hemoglobin \<128 g/L (males) or \<115 g/L (females) and hematocrit \<0.37 L/L (males) or \<0.32 L/L (females) at Screening. Following screening and throughout the study, patient should not donate blood.
26. Any reason which, in the opinion of the PI, would prevent the patient from participating in the study
2. Is planning to become pregnant or impregnate spouse, not using an acceptable method of birth control (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant, or nursing.
3. Patients with combined focal and generalized syndrome as evidenced by severe developmental delay and multiple seizure types, confirmed by EEG (e.g., Lennox-Gastaut syndrome). Patient should also be excluded in case of non-diagnostic information.
4. Has non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
5. Has only seizures that are difficult to count; for example, has seizures that are not clinically observable.
6. Has a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
7. Has a history of status epilepticus in the 6 months prior to Screening.
8. Change in ASM regimen in the last 28 days prior to Screening. No changes in ASMs are allowed throughout the study period.
9. Vagus nerve stimulation (VNS), deep brain stimulation (DBS), responsive neurostimulator system (RNS), or other neurostimulation for epilepsy device implanted or activated \<1 year prior to Screening; stimulation parameters that have been stable for \<3 months; battery life of unit not anticipated to extend for duration of trial; or epilepsy surgery \<1 year prior to Screening.
10. Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt. History of suicidal ideation.
11. Any condition that may impact a patient's ability to follow study procedures or a patient's safety, based on what is known about the pharmacology/toxicology profile of the trial agent(s).
12. Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the PI's opinion, could interfere with the patient's suitability for participation in the study.
13. Has a history or evidence of current significant psychiatric disturbance (e.g., schizophrenia, schizoaffective, or bipolar disorder) that would preclude meaningful participation in the study procedures.
14. A history in the past 2 years or evidence of current alcohol and/or substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders 5th edition.
15. Has had any clinical laboratory abnormalities within the 2 months prior to screening considered of clinical significance by the PI.
16. Is HIV/Hepatitis B/Hepatitis C positive or has a positive urine drug screen.
17. Tobacco use as indicated by \>5 cigarettes per week or the equivalent, 30 days prior to Day -1.
18. Is on concomitant therapy with non-ASMs that are cholinergic.
19. Is currently taking or within the 3 days prior to enrollment has taken Epigallocatechin gallate (EGCG); or consumed foods or drinks containing EGCG, including green, white, or oolong teas and certain black teas, or food containing \>100 grams of carob powder. EGCG cannot be consumed throughout the study.
20. Has participated in any clinical investigational drug or device study within 4 weeks prior to study entry or within 5 half-lives of the clinical investigational drug, whichever is longer.
21. Clinically significant cardiologic abnormalities at Screening. One repeat assessment is allowed per investigator discretion.
1. Abnormal ECG that is, in the investigator's opinion, clinically significant including heart rate (HR) \<50 bpm (average of 3 recordings)
2. PR interval \> 220 ms
3. QRS interval ≥ 120 ms
4. QTcF (QT corrected for heart rate using Fridericia's method) interval \> 450 ms for males and interval \> 475 ms for females
5. Second or third-degree atrioventricular block
6. Any rhythm, other than sinus rhythm, that is interpreted by the investigator to be clinically significant
22. Creatinine clearance \< 90 mL/min, according to the Cockcroft-Gault equation at Screening.
23. Clinically significant vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or HR less than 50 or over 100 bpm) at Screening.
24. Patient has had greater than 2 allergic reactions to an ASM or one serious hypersensitivity reaction to an ASM.
25. Patients who donated 50 to 499 mL of blood within 30 days or more than 499 mL within 56 days prior to Day 1 dosing or have hemoglobin \<128 g/L (males) or \<115 g/L (females) and hematocrit \<0.37 L/L (males) or \<0.32 L/L (females) at Screening. Following screening and throughout the study, patient should not donate blood.
26. Any reason which, in the opinion of the PI, would prevent the patient from participating in the study
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supernus Pharmaceuticals, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Rubin, MD, MBA
Role: STUDY_DIRECTOR
Supernus Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alfred Hospital
Melbourne, , Australia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Australia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
817P202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
NCT05684978
TERMINATED
PHASE4
Bioavailability, Safety, and Tolerability of BIS-001 ER
NCT03156439
COMPLETED
PHASE1
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NCT05159908
COMPLETED
PHASE2
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
NCT00235755
COMPLETED
PHASE3
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00735397
COMPLETED
PHASE3
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
NCT01618695
COMPLETED
PHASE3
An Open-label Study of XEN1101 in Epilepsy
NCT05718817
ENROLLING_BY_INVITATION
PHASE3
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
ACTIVE_NOT_RECRUITING
PHASE4
Human Epilepsy Project 2: Resistant Focal Seizures Study
NCT03531008
COMPLETED
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
NCT02736162
COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629
RECRUITING
PHASE1
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
NCT04714996
UNKNOWN
PHASE2
A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
NCT03198949
COMPLETED
PHASE2
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
NCT01397968
COMPLETED
PHASE2
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00228969
COMPLETED
PHASE2
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
NCT02535091
COMPLETED
PHASE3
Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00215592
COMPLETED
PHASE4
Cenobamate in Adults With Focal-Onset Seizures
NCT05859854
ACTIVE_NOT_RECRUITING
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
NCT00210652
COMPLETED
PHASE2
A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
NCT02033902
COMPLETED
Adjunctive Everolimus Treatment of Refractory Epilepsy
NCT05613166
UNKNOWN
PHASE2
A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
NCT00292461
COMPLETED
PHASE3
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
NCT06425159
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3